SrasV1, PubMed, Checkpoint, bibRecord, 001395

A facile inhibitor screening of SARS coronavirus N protein using nanoparticle-based RNA oligonucleotide.

Identifieur interne : 001395 ( PubMed/Checkpoint ); précédent : 001394; suivant : 001396

A facile inhibitor screening of SARS coronavirus N protein using nanoparticle-based RNA oligonucleotide.

Auteurs : Changhyun Roh [Corée du Sud]

Source :

International journal of nanomedicine [ 1178-2013 ] ; 2012.

RBID : pubmed:22619553

Descripteurs français

KwdFr :
- ARN viral (), ARN viral (génétique), Analyse par réseau de protéines, Antiviraux (), Antiviraux (pharmacologie), Boîtes quantiques, Catéchine (analogues et dérivés), Catéchine (pharmacologie), Conformation d'acide nucléique, Nanomédecine, Nanoparticules, Oligoribonucléotides (), Oligoribonucléotides (génétique), Protéines nucléocapside (antagonistes et inhibiteurs), Protéines nucléocapside (génétique), Séquence nucléotidique, Tests de sensibilité microbienne (), Virus du SRAS (), Virus du SRAS (génétique).
MESH :
- analogues et dérivés : Catéchine.
- antagonistes et inhibiteurs : Protéines nucléocapside.
- génétique : ARN viral, Oligoribonucléotides, Protéines nucléocapside, Virus du SRAS.
- pharmacologie : Antiviraux, Catéchine.
- ARN viral, Analyse par réseau de protéines, Antiviraux, Boîtes quantiques, Conformation d'acide nucléique, Nanomédecine, Nanoparticules, Oligoribonucléotides, Séquence nucléotidique, Tests de sensibilité microbienne, Virus du SRAS.

English descriptors

KwdEn :
- Antiviral Agents (chemistry), Antiviral Agents (pharmacology), Base Sequence, Catechin (analogs & derivatives), Catechin (pharmacology), Microbial Sensitivity Tests (methods), Nanomedicine, Nanoparticles, Nucleic Acid Conformation, Nucleocapsid Proteins (antagonists & inhibitors), Nucleocapsid Proteins (genetics), Oligoribonucleotides (chemistry), Oligoribonucleotides (genetics), Protein Array Analysis, Quantum Dots, RNA, Viral (chemistry), RNA, Viral (genetics), SARS Virus (drug effects), SARS Virus (genetics).
MESH :
- chemical , analogs & derivatives : Catechin.
- chemical , antagonists & inhibitors : Nucleocapsid Proteins.
- chemical , chemistry : Antiviral Agents, Oligoribonucleotides, RNA, Viral.
- chemical , genetics : Nucleocapsid Proteins, Oligoribonucleotides, RNA, Viral.
- chemical , pharmacology : Antiviral Agents, Catechin.
- drug effects : SARS Virus.
- genetics : SARS Virus.
- methods : Microbial Sensitivity Tests.
- Base Sequence, Nanomedicine, Nanoparticles, Nucleic Acid Conformation, Protein Array Analysis, Quantum Dots.

Abstract

Hundreds of million people worldwide have been infected with severe acute respiratory syndrome (SARS), and the rate of global death from SARS has remarkably increased. Hence, the development of efficient drug treatments for the biological effects of SARS is highly needed. We have previously shown that quantum dots (QDs)-conjugated RNA oligonucleotide is sensitive to the specific recognition of the SARS-associated coronavirus (SARS-CoV) nucleocapsid (N) protein. In this study, we found that a designed biochip could analyze inhibitors of the SARS-CoV N protein using nanoparticle-based RNA oligonucleotide. Among the polyphenolic compounds examined, (-)-catechin gallate and (-)-gallocatechin gallate demonstrated a remarkable inhibition activity on SARS-CoV N protein. (-)-catechin gallate and (-)-gallocatechin gallate attenuated the binding affinity in a concentrated manner as evidenced by QDs-conjugated RNA oligonucleotide on a designed biochip. At a concentration of 0.05 μg mL(-1), (-)-catechin gallate and (-)-gallocatechin gallate showed more than 40% inhibition activity on a nanoparticle-based RNA oligonucleotide biochip system.

DOI: 10.2147/IJN.S31379
PubMed: 22619553

Affiliations:

Corée du Sud

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 001359
to stream PubMed, to step Curation: 001359

Links to Exploration step

pubmed:22619553

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A facile inhibitor screening of SARS coronavirus N protein using nanoparticle-based RNA oligonucleotide.</title>
<author><name sortKey="Roh, Changhyun" sort="Roh, Changhyun" uniqKey="Roh C" first="Changhyun" last="Roh">Changhyun Roh</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Biotechnology, Advanced Radiation Technology Institute (ARTI), Korea Atomic Energy Research Institute (KAERI), Jeongeup, Republic of Korea. chroh@kaeri.re.kr</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of Biotechnology, Advanced Radiation Technology Institute (ARTI), Korea Atomic Energy Research Institute (KAERI), Jeongeup</wicri:regionArea>
<wicri:noRegion>Jeongeup</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22619553</idno>
<idno type="pmid">22619553</idno>
<idno type="doi">10.2147/IJN.S31379</idno>
<idno type="wicri:Area/PubMed/Corpus">001359</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001359</idno>
<idno type="wicri:Area/PubMed/Curation">001359</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001359</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001395</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001395</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A facile inhibitor screening of SARS coronavirus N protein using nanoparticle-based RNA oligonucleotide.</title>
<author><name sortKey="Roh, Changhyun" sort="Roh, Changhyun" uniqKey="Roh C" first="Changhyun" last="Roh">Changhyun Roh</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Biotechnology, Advanced Radiation Technology Institute (ARTI), Korea Atomic Energy Research Institute (KAERI), Jeongeup, Republic of Korea. chroh@kaeri.re.kr</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of Biotechnology, Advanced Radiation Technology Institute (ARTI), Korea Atomic Energy Research Institute (KAERI), Jeongeup</wicri:regionArea>
<wicri:noRegion>Jeongeup</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">International journal of nanomedicine</title>
<idno type="eISSN">1178-2013</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (chemistry)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Base Sequence</term>
<term>Catechin (analogs & derivatives)</term>
<term>Catechin (pharmacology)</term>
<term>Microbial Sensitivity Tests (methods)</term>
<term>Nanomedicine</term>
<term>Nanoparticles</term>
<term>Nucleic Acid Conformation</term>
<term>Nucleocapsid Proteins (antagonists & inhibitors)</term>
<term>Nucleocapsid Proteins (genetics)</term>
<term>Oligoribonucleotides (chemistry)</term>
<term>Oligoribonucleotides (genetics)</term>
<term>Protein Array Analysis</term>
<term>Quantum Dots</term>
<term>RNA, Viral (chemistry)</term>
<term>RNA, Viral (genetics)</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (genetics)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ARN viral ()</term>
<term>ARN viral (génétique)</term>
<term>Analyse par réseau de protéines</term>
<term>Antiviraux ()</term>
<term>Antiviraux (pharmacologie)</term>
<term>Boîtes quantiques</term>
<term>Catéchine (analogues et dérivés)</term>
<term>Catéchine (pharmacologie)</term>
<term>Conformation d'acide nucléique</term>
<term>Nanomédecine</term>
<term>Nanoparticules</term>
<term>Oligoribonucléotides ()</term>
<term>Oligoribonucléotides (génétique)</term>
<term>Protéines nucléocapside (antagonistes et inhibiteurs)</term>
<term>Protéines nucléocapside (génétique)</term>
<term>Séquence nucléotidique</term>
<term>Tests de sensibilité microbienne ()</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (génétique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Catechin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Nucleocapsid Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiviral Agents</term>
<term>Oligoribonucleotides</term>
<term>RNA, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Nucleocapsid Proteins</term>
<term>Oligoribonucleotides</term>
<term>RNA, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Catechin</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Catéchine</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines nucléocapside</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ARN viral</term>
<term>Oligoribonucléotides</term>
<term>Protéines nucléocapside</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Microbial Sensitivity Tests</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Catéchine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Base Sequence</term>
<term>Nanomedicine</term>
<term>Nanoparticles</term>
<term>Nucleic Acid Conformation</term>
<term>Protein Array Analysis</term>
<term>Quantum Dots</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>ARN viral</term>
<term>Analyse par réseau de protéines</term>
<term>Antiviraux</term>
<term>Boîtes quantiques</term>
<term>Conformation d'acide nucléique</term>
<term>Nanomédecine</term>
<term>Nanoparticules</term>
<term>Oligoribonucléotides</term>
<term>Séquence nucléotidique</term>
<term>Tests de sensibilité microbienne</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Hundreds of million people worldwide have been infected with severe acute respiratory syndrome (SARS), and the rate of global death from SARS has remarkably increased. Hence, the development of efficient drug treatments for the biological effects of SARS is highly needed. We have previously shown that quantum dots (QDs)-conjugated RNA oligonucleotide is sensitive to the specific recognition of the SARS-associated coronavirus (SARS-CoV) nucleocapsid (N) protein. In this study, we found that a designed biochip could analyze inhibitors of the SARS-CoV N protein using nanoparticle-based RNA oligonucleotide. Among the polyphenolic compounds examined, (-)-catechin gallate and (-)-gallocatechin gallate demonstrated a remarkable inhibition activity on SARS-CoV N protein. (-)-catechin gallate and (-)-gallocatechin gallate attenuated the binding affinity in a concentrated manner as evidenced by QDs-conjugated RNA oligonucleotide on a designed biochip. At a concentration of 0.05 μg mL(-1), (-)-catechin gallate and (-)-gallocatechin gallate showed more than 40% inhibition activity on a nanoparticle-based RNA oligonucleotide biochip system.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22619553</PMID>
<DateCompleted><Year>2012</Year>
<Month>09</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>12</Month>
<Day>31</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1178-2013</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>7</Volume>
<PubDate><Year>2012</Year>
</PubDate>
</JournalIssue>
<Title>International journal of nanomedicine</Title>
<ISOAbbreviation>Int J Nanomedicine</ISOAbbreviation>
</Journal>
<ArticleTitle>A facile inhibitor screening of SARS coronavirus N protein using nanoparticle-based RNA oligonucleotide.</ArticleTitle>
<Pagination><MedlinePgn>2173-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2147/IJN.S31379</ELocationID>
<Abstract><AbstractText>Hundreds of million people worldwide have been infected with severe acute respiratory syndrome (SARS), and the rate of global death from SARS has remarkably increased. Hence, the development of efficient drug treatments for the biological effects of SARS is highly needed. We have previously shown that quantum dots (QDs)-conjugated RNA oligonucleotide is sensitive to the specific recognition of the SARS-associated coronavirus (SARS-CoV) nucleocapsid (N) protein. In this study, we found that a designed biochip could analyze inhibitors of the SARS-CoV N protein using nanoparticle-based RNA oligonucleotide. Among the polyphenolic compounds examined, (-)-catechin gallate and (-)-gallocatechin gallate demonstrated a remarkable inhibition activity on SARS-CoV N protein. (-)-catechin gallate and (-)-gallocatechin gallate attenuated the binding affinity in a concentrated manner as evidenced by QDs-conjugated RNA oligonucleotide on a designed biochip. At a concentration of 0.05 μg mL(-1), (-)-catechin gallate and (-)-gallocatechin gallate showed more than 40% inhibition activity on a nanoparticle-based RNA oligonucleotide biochip system.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roh</LastName>
<ForeName>Changhyun</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Division of Biotechnology, Advanced Radiation Technology Institute (ARTI), Korea Atomic Energy Research Institute (KAERI), Jeongeup, Republic of Korea. chroh@kaeri.re.kr</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2012</Year>
<Month>05</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>New Zealand</Country>
<MedlineTA>Int J Nanomedicine</MedlineTA>
<NlmUniqueID>101263847</NlmUniqueID>
<ISSNLinking>1176-9114</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019590">Nucleocapsid Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009843">Oligoribonucleotides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C099602">nucleocapsid protein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0C056HB16M</RegistryNumber>
<NameOfSubstance UI="C417940">gallocatechin gallate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>78OW2GLG8Q</RegistryNumber>
<NameOfSubstance UI="C417939">catechin gallate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>8R1V1STN48</RegistryNumber>
<NameOfSubstance UI="D002392">Catechin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002392" MajorTopicYN="N">Catechin</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D050997" MajorTopicYN="N">Nanomedicine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009690" MajorTopicYN="N">Nucleic Acid Conformation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019590" MajorTopicYN="N">Nucleocapsid Proteins</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009843" MajorTopicYN="N">Oligoribonucleotides</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D040081" MajorTopicYN="N">Protein Array Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045663" MajorTopicYN="N">Quantum Dots</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RNA oligonucleotide</Keyword>
<Keyword MajorTopicYN="N">SARS</Keyword>
<Keyword MajorTopicYN="N">inhibitor</Keyword>
<Keyword MajorTopicYN="N">quantum dots</Keyword>
<Keyword MajorTopicYN="N">screening</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year>
<Month>5</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2012</Year>
<Month>5</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2012</Year>
<Month>9</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">22619553</ArticleId>
<ArticleId IdType="doi">10.2147/IJN.S31379</ArticleId>
<ArticleId IdType="pii">ijn-7-2173</ArticleId>
<ArticleId IdType="pmc">PMC3356205</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Clin Invest. 2001 Jan;107(2):135-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11160126</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer. 2010 Jan 1;116(1):164-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19894226</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 May 24;361(9371):1779-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12781537</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 Dec 18;349(25):2468-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14681520</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2004 May;42(5):2306-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15131220</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Chem. 2004 Jun;50(6):1050-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15054079</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2004 Jul;42(7):2884-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15243033</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1970 Aug 15;227(5259):680-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5432063</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anal Biochem. 1976 May 7;72:248-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">942051</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 1989 Jun 26;17(12):4847-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2526320</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Pharmacol. 1992 Mar 17;43(6):1167-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1562270</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 1993 Sep 20;233(2):261-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8377202</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Nov;79(21):13285-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16227251</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2005 Nov;26(5):343-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16323269</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Phys Chem B. 2006 Feb 16;110(6):2910-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16471901</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Allergy Clin Immunol. 2006 Dec;118(6):1369-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17157668</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neuroimmunol. 2007 Mar;184(1-2):17-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17222462</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Nutr Biochem. 2007 May;18(5):287-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17049833</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2007 Oct 15;67(20):9809-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17942911</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Nutr. 2008 May;99 E Suppl 1:ES60-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18503736</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2008 Oct 10;380(1):99-108</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18703211</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2009 Mar;7(3):226-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19198616</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biomed Res. 2009 Aug;30(4):207-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19729851</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anticancer Res. 2009 Oct;29(10):4025-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19846946</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Phytochemistry. 2002 Jun;60(3):205-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12031439</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Corée du Sud</li>
</country>
</list>
<tree><country name="Corée du Sud"><noRegion><name sortKey="Roh, Changhyun" sort="Roh, Changhyun" uniqKey="Roh C" first="Changhyun" last="Roh">Changhyun Roh</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001395 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001395 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:22619553
   |texte=   A facile inhibitor screening of SARS coronavirus N protein using nanoparticle-based RNA oligonucleotide.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:22619553" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

A facile inhibitor screening of SARS coronavirus N protein using nanoparticle-based RNA oligonucleotide.

A facile inhibitor screening of SARS coronavirus N protein using nanoparticle-based RNA oligonucleotide.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki